Cyclooxygenase-2 expression:: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast

被引:32
作者
Tan, KB
Yong, WP
Putti, TC
机构
[1] Natl Univ Singapore, Natl Univ Hosp, Dept Pathol, Singapore 119074, Singapore
[2] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore 117548, Singapore
关键词
COX-2; intraductal carcinoma; breast cancer; immunohistochemistry; chemoprevention; adjuvant therapy;
D O I
10.1111/j.1365-2559.2004.01774.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To study cyclooxygenase-2 (COX-2) expression in ductal carcinoma in situ (DCIS) of the breast and its association with histological features. COX-2, an inducible prostaglandin synthase, has been shown to be important in mammary carcinogenesis, being associated with increased tumour size and unfavourable outcome in breast cancer. Animal studies indicate that COX-2 inhibition is effective in the prevention and treatment of mammary cancers. Methods and results: Fifty-one cases of DCIS diagnosed during 1990-2000 were reviewed. Immunohistochemistry for COX-2 was performed and the COX-2 staining scores were correlated with histological features. The majority of cases [41 of 51 (80%)] had positive COX-2 staining, of which 13 cases (25%) had strong staining. High nuclear grade DCIS was significantly associated with increased COX-2 staining (P = 0.04). Conclusions: High-grade lesions are known to be associated with a higher recurrence rate following excision and are often oestrogen receptor negative, and as such, may be less responsive to adjuvant tamoxifen therapy. There is a need to examine further the role of COX-2 expression in DCIS, as both a prognostic and predictive factor.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 26 条
[1]  
Alshafie GA, 2000, ONCOL REP, V7, P1377
[2]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[3]  
BOBROW LG, 1994, SEMIN DIAGN PATHOL, V11, P199
[4]  
BUR ME, 1992, CANCER-AM CANCER SOC, V69, P1174
[5]  
Ellis IO, 1999, HISTOPATHOLOGY, V35, P470
[6]   Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Mamounas, E ;
Smith, R ;
Begovic, M ;
Dimitrov, NV ;
Margolese, RG ;
Kardinal, CG ;
Kavanah, MT ;
Fehrenbacher, L ;
Oishi, RH .
LANCET, 1999, 353 (9169) :1993-2000
[7]   The contributions of cyclooxygenase-2 to tumor angiogenesis [J].
Gately, S .
CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) :19-27
[9]   COX-2 inhibition and prevention of cancer [J].
Giercksky, KE .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (05) :821-833
[10]  
Half E, 2002, CANCER RES, V62, P1676